Skip to main content
PLOS One logoLink to PLOS One
. 2021 Feb 12;16(2):e0244596. doi: 10.1371/journal.pone.0244596

Fluctuations in influenza-like illness epidemics and suicide mortality: A time-series regression of 13-year mortality data in South Korea

Sun Jae Jung 1,2, Sung-Shil Lim 3, Jin-Ha Yoon 1,3,*
Editor: Mrinmoy Sanyal4
PMCID: PMC7880447  PMID: 33577567

Abstract

Aims

We explored the association between influenza epidemic and suicide mortality rates in a large population using a time-series regression of 13-year mortality data in South Korea.

Methods

Weekly suicide mortalities and influenza-like illness (ILI) were analyzed using time series regression. Regression coefficient for suicide mortality based on percentage change of ILI was calculated using a quasi-Poisson regression. Non-linear distributed lag models with quadratic function up to 24 weeks were constructed.

Results

The association between ILI and suicide mortality increased significantly up to 8 weeks post-influenza diagnosis. A significant positive association between ILI and suicide mortality was observed from 2009, when a novel influenza A(H1N1)pdm09 virus provoked a worldwide pandemic. No meaningful association between these factors was observed before 2009.

Conclusion

There was a significant positive relationship between ILI and suicide mortality after 2009, when a novel influenza A(H1N1)pdm09 virus provoked a worldwide pandemic.

Introduction

In 2009, the U.S. Centers for Disease Control and Prevention reported four cases of previously healthy children who developed neurological complications after being infected with pandemic influenza A (H1N1) [1]. Similar case reports from other countries have raised concerns regarding the association between influenza infection and neuropsychiatric symptoms such as depression, anxiety, changes in mental status, and seizures [2]. However, the results were conflicting, and a systematic review [3] found that the available evidence was insufficient to guide a definite conclusion regarding the association between influenza infection and neuropsychiatric symptoms. Especially in South Korea, one study dealt with the adverse psychiatric events after the treatment of H1N1, oseltamivir [4], but evidence lacked for the association between infectious epidemic itself and neuropsychiatric symptoms. In addition, a new virus subtype labeled novel influenza A(H1N1)pdm09 first emerged in 2009, even though the influenza subtype of H1N1 existed before 2009.

In population studies, the total numbers of suicide mortality have shown seasonal peaks especially during the early spring, which usually falls in February to March in Korea. These peaks overlap with seasonal peaks in epidemics of upper respiratory tract infection, which may affect the nose, throat, sinus, and larynx. In a study conducted in South Korean children with lower respiratory infections who were aged less than 18 years, two distinct peaks in viral upper respiratory tract infection was noted yearly, each during April-May and October-November [5]. The development of prevention strategies relies on an understanding of the cause of suicide mortality at a population level. However, little available evidence has supported the association between a new influenza (H1N1) virus pandemic, novel influenza A(H1N1)pdm09, and suicide in a substantial number of people, with respect to periodic changes. Therefore, we explored the association between influenza-like illness(ILI) infection and suicide mortality rates across a large population using time-series regression.

Methods

Ethical approval and consent to participate

The subject information was blinded prior to analysis. The Institutional Review Board (IRB) of the Yonsei University Health System approved the current study design (IRB number: Y-2017-0100).

Study population

We obtained data for this study from the Korea Centers for Disease Control and Prevention (KCDC). As the information regarding virus genotyping was unavailable, we could not distinguish between H1N1 infection and other flu-like illness, however, we obtained information about ILI outpatient visits (per 1,000 people) weekly ranging from the 35th International Organization for Standardization (ISO) week in 2004 to the 52th ISO week in 2017. The Korean government made surveillance system for ILI at 53 hospitals, using geographic stratification. By law [6], every physician are required to report the number of patients who are suspected to suffer from ILI. The government also issued a guideline on how to define ILI for proper reporting (see S1 Box below). In this guideline, physicians should report patients with clinical symptoms with one or more virus-specific biomarkers, including influenza virus antibody or viral gene, from specimen as ILI cases.

Suicide mortality data during the same period were acquired from the national death records of the Korea National Statistical Office. This record covers all deaths throughout South Korea and classifies the causes based on the International Classification of Diseases, 10th Edition (ICD-10). To capture suicide along with intentional self-harm and sequelae of intentional self-harm, we selected X60-X84 and Y870 codes for the outcome. We included the entire population in the final analysis. For the control analysis, we obtained cancer mortality from the same data to demonstrate that non-suicide death was not related to ILI. Death due to cancer was coded as C00~C99 according to the ICD-10 code.

Statistical analysis

We used the weekly percent of ILI and weekly number of suicide. As the number of weekly suicide mortality showed seasonality, we fitted linear function with sine and cosine formulae [7]. We used 52.18 (365.25/7) for cyclic frequency, as not every year had 52 weeks. Generalized additive model (GAM) was used for cubic spline of seasonality, and minimal values of Akaike Information Criterion (AIC) or Bayesian information criterion (BIC) were used in the model fitting. The formula for time series analysis with GAM, as shown below.

g(suicidet)=β0+f1(ILItl)+f2(Seasont)+f3(Weekt)+ε(t)

where: fs(xt)=i=1kbi(xt)βi,βi is the weight value applied to the ith basis function (bi), so the fs(xt) is smooth function of covariates xt. Suicide(t) is weekly(t) number of suicides, and ILI(t-l) is corresponding weekly ILI with lag time 0 to 8 weeks. Season and long-term trend by week are confounding factors. Every step of model building were simulated by degree of freedom (df) from 2 to 200 in the generalized linear model or GAM, and graphical approach was used to detect the optimal df of GAM spline parameter for minimal AIC or BIC. If there was no change point of AIC until a degree of freedom of 200 simulations, then BIC was used. The degree of freedom of GAM spline parameter was 5 for seasonality and 39 for other remnant trends. Then, after controlled seasonality, The partial autocorrelation plot of residuals showed no cyclic pattern.

The same simulation was used to select a non-linear distributed lag model from 0 to 24 weeks with a quadratic function. Rate ratios (RRs) for suicide mortality with 95% confidence intervals (95% CIs) based on %ILI increments were calculated using a quasi-Poisson regression to address the problem of over-dispersion. Analyses for the effects of swine flu pandemics were stratified as before and during/after 2009. For the control analysis, all processes were replicated with cancer mortality as the outcome. Data from August 2004 to December 2017 were used analysis. All statistical analyses and graphics were generated using R program, ver. 3.5 (R Foundation for Statistical Computing, Vienna, Austria).

Results

A total of 179,839 suicide mortalities were recorded during the study period (average number of annual Korean population was 49,093,917). In terms of annual suicide deaths, 12,043 cases were reported in 2005, followed by a peak of 15,914 cases in 2011 and a gradual decrease to 12,429 cases in 2017, with seasonal fluctuations (Fig 1). There were monthly or seasonal variations in the number of suicide deaths, with peaks occurring from March to May (Fig 2). The median (interquartile range) number of weekly suicide was 278 (250–312) in March, 295 (267–320) in April, and 286 (259–321) in May. However, we could not find a significant difference in the magnitude of the association between ILI and suicide mortality across every month by linear regression.

Fig 1. Weekly numbers of suicides and influenza-like illnesses per 100 outpatients from 2004 to 2017.

Fig 1

β (Beta) indicates the change in weekly suicide numbers, considering the % increment in influenza-like illness cases; red dot line show weekly number of suicide after adjusting time series factors, and red shadow indicates 95% confidence interval of the estimated weekly suicide rate, which was assessed using a generalized additive model; blue line show influenza like illness per 100 outpatients without lag time, and horizontal line indicates the year 2009.

Fig 2. Monthly variation of weekly numbers of suicides during study period.

Fig 2

A statistically significant increment in ILI rate was observed starting in 2009, in a time series regression analysis. The relationship between the ILI number per 1,000 people and suicide deaths exhibited a significant positive association since 2009 (β = 0.013, P = 0.018), but not before 2009 (β = -0.066, P = 0.214) (Fig 1).

The RRs (95% CIs, p value) for suicide mortality based on ILIs were as follows: 1.007 (1.003–1.012, <0.001) with no lag, 1.007 (1.003–1.011, <0.001) with a 1-week lag, 1.006 (1.003–1.010, 0.001) with a 2-week lag, 1.006 (1.002–1.009, 0.001) with a 3-week lag, 1.005 (1.001–1.008, 0.003) with a 4-week lag, 1.004 (1.001–1.007, 0.006) with a 5-week lag, 1.004 (1.001–1.007, 0.011) with a 6-week lag, 1.004 (1.001–1.007, 0.020) with a 7-week lag, and 1.003 (1.000–1.007, 0.033) with an 8-week lag, respectively (Fig 3). From week 9, the RRs of suicide mortality were attenuated, and the relationship of ILI with suicide death became insignificant (p values > 0.05). In the control analysis, when comparing cancer mortality with suicidal mortality, we could not find any significant relationship between influenza symptoms and cancer mortality (data not shown).

Fig 3. Association between suicide and influenza according to different lag periods.

Fig 3

Discussion

In our study using population data, we identified a significant positive association between ILI and suicide mortality only after the 2009 pandemic, the year in which a novel influenza A(H1N1)pdm09 virus provoked a worldwide pandemic. No meaningful association between these factors was observed before 2009. The association between ILI and suicide mortality increased significantly up to 8 weeks after the onset of ILI symptoms, but 9 weeks after did not.

Corresponding to our results which indicated a significant positive association between ILI number and suicide mortality, one large prospective cohort study [8] using the Danish Civil Registration System showed similar results, supporting our study findings. Among 7,221,578 Danish individuals from 1980 to 2011, hospitalization by viral infection increased the suicide mortality incidence by 1.26 times, compared with control population after adjusting for sex, age, calendar period, cohabitation status, socioeconomic status, and comorbidity. Another prior study [9] of various anti-viral antibody titers in 257 individuals from the U.S. identified a significant relationship between suicidal behavior and influenza B, but not influenza A infection; and a significant association was observed between depression and Influenza A infection. This discrepancy might be attributable to the relatively low statistical power of the previous study. Moreover, suicidal behavior was examined only among people who reported depressive symptoms. Therefore, patients who exhibited suicidal behavior after influenza infection may have not had sufficient time to report depressive symptoms. A large case-control study [2] based on the U.K. Clinical Practice Research Datalink identified an increased risk of depression among people with previous influenza infection, which was only significant 30 days after influenza diagnosis.

Another study of 119 older individuals from the U.S. examined symptoms of depression before and after influenza vaccination and observed no significant change [10]. The possibility of suicidal behavior as an adverse effect of oseltamivir was questioned; however, published studies, including randomized controlled trials [11, 12] and some observational cohort studies [13], did not find any significant association. A nationally representative case-crossover study [14] from the U.S. analyzed five contemporary influenza seasons (2009–2013) and identified no significant association between oseltamivir use and suicidal behavior. Another longitudinal study [15], including 1.3 million young Danish people, examined the effect of infections and anti-infective agents on suicidal behavior using nationwide registration data, and suggested that although there was a significant positive association between any anti-infective prescription and self-harm, there was no statistically significant relationship between the use of anti-viral agents and suicidal behavior. In our preliminary analysis based on a sampled Korean National Health Insurance (NHI) Cohort, 8,289 patients were diagnosed with influenza during 2010–2013, and 1,835 were exposed to oseltamivir (results not shown); however, the relationship between oseltamivir use and suicidal behavior could not be determined due to the small sample size (three suicide cases in sampled cohort). It has been known that total monthly rate of antibiotic use was highly cross-correlated with the monthly detection rate of influenza virus in South Korea (cross-correlation coefficient 0.47) [16], so it is possible that people who had viral infection might have antibiotic treatment. However, there is a lack of evidence that antibiotics increase the risk of suicidal behavior. Among the antibiotics, fluroquinolone was reported to have some side effects on mental health according to the U.S. Food and Drug Administration; however, suicidal behavior was not included as a side effect.

The biological characteristics of a new virus subtype labeled novel influenza A(H1N1)pdm09 were considerably different from those of the classic (previous) seasonal influenza A(H1N1), which exhibited higher severity in clinical symptoms and strong transmission tendency [14, 17]. The difference might have resulted in a stronger association between ILI and suicidal mortality after 2009. Nevertheless, we could not obtain the weekly data of novel influenza A(H1N1)pdm09 from KCDC, or confirm the magnitude of current association contributed by novel influenza A(H1N1)pdm09.

The etiology of neuropsychiatric symptom development after viral infection remains unknown, and it is unclear whether the virus or corresponding immune response is the causative factor. Several inflammatory cytokines, including interleukin (IL)-2, IL-6, and inferteron-alpha, are assumed to generate the kynurenine neurotoxic metabolite in individuals with suicidal tendencies [1820] and affect the serotonin system [21], which is a pathway well-known for its influence of depressive disorders [22, 23]: dysregulation of the serotonin system by inflammatory cytokines could partially explain suicidal ideation or behavior among people [24]. Also, a respiratory virus affecting the nose and upper respiratory tract, including sinus infections and allergic rhinitis, has been mentioned as being responsible for central nervous system(CNS) pathologies; viruses such as influenza, coronavirus, and human respiratory syncytial virus are known as a neuropathological virus. Through the neurons which innervate the peripheral organ and olfactory neurons, these viruses enter the CNS, reach the whole brain and cerebrospinal fluid (CSF), and cause demyelination. Simultaneously, primary glial cultures under these conditions have shown the secretion of cytokines in CSF, such as IL-6, IL-15, TNF-α, and CXCL9/10 [25].

In our study, we found lags shorter than 8 weeks with significantly positive association between ILI and suicidal behavior, and the result from Denmark study [8] did not apply any lag, which could imply that their result represent more immediate effect of infection and suicide death. Neuroinflammation can be one of the explanations linking the virus infection and suicidal behavior. Immediate neuroinflammatory changes, including sudden increase in pro-inflammatory cytokines, can exhibit brief symptoms; whereas neuroinflammatory priming, both peripheral and central signaling cells—particularly microglia, exhibit a long-term and derivative change. After stress, primed microloglia produce new “silent” immune machinery, which causes immune insult and a hyperinflammatory response [26]. Beyond biological mechanisms, the lag between ILI epidemics and suicide include population level analytics, such as window time among exposure and clinical symptoms, or hospitalization.

However, our result indicating seasonal variations in suicidal deaths should be interpreted with other seasonal factors, such as sunlight and pollen exposure. The results from about 43,000 people in Finland showed a significant peak in suicide deaths between May and June, which tend to have the longest sunlight exposure of the year, and the lag period for this association was around 1 month [27]. Contrary to this study, our results showed significant peak of suicidal mortality from March to May, which shows moderate sunlight exposure. Usually, the solstice in South Korea happens in December; therefore, even if we consider the maximum lag to be 8 weeks, there is still a possibility for period overlap due to sunlight exposure. In addition, pollen counts were suspected to be a factor associated with suicide rate [28]; however, a study with data from 42 counties of the continental U.S. did not replicate the significant association [29]. Furthermore, our current model controlled seasonal effects using GAM and time series model, and those adjustments did not attenuate the association between ILI fluctuation and suicide.

The socio-economic difference between times before the 2009 pandemic and post-2009 pandemic should also be considered. In our previous study using national statistics in South Korea, we found an increased suicide rate during the 2008 global financial crisis. We could observe a rise in suicidal mortality, especially among elderly male office workers and managers [30]. Possible interaction may exist between job status, sex, and ILI with suicidal deaths in our data. The novel coronavirus outbreak in 2019 (COVID-19) would differ from novel Influenza A(H1N1)pdm09, in terms of the proportion of affected people, their social influence, and the absence of vaccine and treatment, which may trigger suicidal behavior in more socio-economic context. Further analyses for the adverse mental health outcomes, including suicidal behavior due to these types of respiratory neurotropic viruses, are warranted.

To our knowledge, our study is the first to evaluate the association between ILI infection and suicidal mortality in an Asian population. One report [31] from Hong Kong examined nine cases of neurological complications after H1N1 infection, but did not report the number of suicidal attempts. We utilized nationally representative population data of South Korea, which provided sufficient statistical power to identify significant associations. The time-series analysis enabled us to consider the repeated temporality of both suicidal mortality and ILIs.

However, this study utilized the grouped data, and individual causality could not be interpreted. During modeling, we could not consider important confounders and mediators, including socio-economic and life-style factors or comorbidities. Similarly, there could have been unmeasured confounders such as allergic rhinitis (peaks in airborne pollen), sunlight exposure, and secondary bacterial infections (e.g. sinus infections) after influenza infection, which are also important factors of suicidal behavior, and are associated with seasonal variation.

Various studies showed gender differences in suicidal behavior, and these differences may contribute to biological and social aspects [32]. Regarding viral infection, inflammation and immune response also react differently according to gender [33]. However, we could not perform a gender-specific analysis, since there was no gender-specific information on ILI rate that could be obtained from the original KCDC data. Also, as the information regarding virus genotyping was unavailable, we could not distinguish between H1N1 infection and other flu-like illness.

The dates of ILI diagnosis did not fully represent the true dates of infection. As we used data collected from actual hospitals, the estimates likely did not capture the precise association between the time of the last ILI and suicidal death. Our current results could not confirm whether novel influenza A(H1N1)pdm09 is the cause of suicidal behavior, due to the lack of weekly information about pathologic subtype. Moreover, age-specific associations could not be identified, as age-specific ILI parameters were unavailable. In addition, as for the potential relationship between influenza vaccination and suicidal behavior, we could not find relevant published research to support the relationship in a population study with a substantial size. Also, we were unable to obtain information on vaccination history in the individual level. Further research to elucidate this relationship is warranted. The U.S. Center for Disease Control and Prevention [34] and the Institute of Medicine Committee to Review Adverse Effects of Vaccines [35] stated that there is no confirmed adverse effect of influenza vaccine on any of neuropsychiatric adverse events, including brain inflammation, encephalopathy, Acute Disseminated Encephalomyelitis, optic neuritis [36], and Guillain-Barre Syndrome [37]. Furthermore, we could not obtain information regarding hospitalization and medication prescription by individuals, since we used national statistics. However, the average hospitalization duration due to ILIs in South Korea is reported to be relatively short (2–3 days) [6], and every hospitalization decision is made during the outpatient visit, including emergency unit visit; therefore, outpatient data was considered to be more sensitive in capturing the influenza cases. As we mentioned earlier, previous studies regarding the relationship between oseltamivir and suicidal behavior were not evident. However, it is possible that other medications for treating flu symptoms could provoke suicidal ideation. For example, ephedrine, a bronchodilator prescribed in severe cold symptoms, is known to have the side effect of suicidal tendencies [38]. In further studies, information about medication after influenza diagnosis should be also considered, in order to clarify which step affects increased suicidal behavior.

Conclusions

We found a significant positive relationship between ILIs and suicidal mortality after 2009, when a novel influenza A(H1N1)pdm09 virus provoked a worldwide pandemic. The association remained significant until 8 weeks after the ILI development. Further studies with individual-level data are needed to confirm the effects of influenza A infection on suicidal behavior and guide population-based prevention strategies.

Supporting information

S1 Box. Korean government’s guidelines for reporting “influenza-like illness”.

(DOCX)

Data Availability

Data are available from the Korea statistical information system (KOSIS) Statistics DB Internet (http://kosis.kr/eng). The detail step is following: 1) mdis.kostat.go.kr, 2) Sign Up, 3) go to death record data under public health sector, 4) choose period of data set, 5) and download. Influenza monitoring data from 2004 to 2018 was available from KCDC website without any requirement for permission (http://www.cdc.go.kr/npt/biz/npp/iss/influenzaStatisticsMain.do).

Funding Statement

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Science and ICT (NRF-2019R1A4A1028155) (to SJJ). This work was supported by Korea Health Industry Development Institute through “Social and Environmental Risk Research” funded by Ministry of Health & Welfare (HI19C0052) (to JHY). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Kitcharoen S, Pattapongsin M, Sawanyawisuth K, Angela V, Tiamkao S. Neurologic manifestations of pandemic (H1N1) 2009 virus infection. Emerg Infect Dis. 2010;16(3):569–70. 10.3201/eid1603.091699 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bornand D, Toovey S, Jick SS, Meier CR. The risk of new onset depression in association with influenza—A population-based observational study. Brain Behav Immun. 2016;53:131–7. 10.1016/j.bbi.2015.12.005 WOS:000372377500015. [DOI] [PubMed] [Google Scholar]
  • 3.Gharbawy D, Tadrous M, Suda K. Does depression lead to influenza?—A systematic literature analysis. Journal of affective disorders. 2012;138(1–2):41–5. 10.1016/j.jad.2011.12.037 . [DOI] [PubMed] [Google Scholar]
  • 4.Son P, Choi J, Lee S, Park SS, Choi E, Yoo B-K, et al. Psychiatric Symptoms after Taking Oseltamivir in a Child and Its Causality Assessment. Korean J Clin Pharm. 2019;29(1):56–60. Epub 03/31. 10.24304/kjcp.2019.29.1.56 [DOI] [Google Scholar]
  • 5.Lee SJ, Lee SH, Ha EK, Sheen YH, Sung MS, Jung Y-H, et al. Prevalence of respiratory virus infection with regard to age, sex, and seasonality factors: A single center experience against children hospitalized during the 10 years. Allergy Asthma Respir Dis. 2017;5(6):320–5. [Google Scholar]
  • 6.Park M. Infectious disease-related laws: prevention and control measures. Epidemiol Health. 2017;39:e2017033 Epub 2017/08/05. 10.4178/epih.e2017033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Stolwijk AM, Straatman H, Zielhuis GA. Studying seasonality by using sine and cosine functions in regression analysis. 1999;53(4):235–8. 10.1136/jech.53.4.235 %JJournalofEpidemiologyandCommunityHealth [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lund-Sorensen H, Benros ME, Madsen T, Sorensen HJ, Eaton WW, Postolache TT, et al. A Nationwide Cohort Study of the Association Between Hospitalization With Infection and Risk of Death by Suicide. JAMA Psychiatry. 2016;73(9):912–9. 10.1001/jamapsychiatry.2016.1594 . [DOI] [PubMed] [Google Scholar]
  • 9.Okusaga O, Yolken RH, Langenberg P, Lapidus M, Arling TA, Dickerson FB, et al. Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts. Journal of affective disorders. 2011;130(1–2):220–5. 10.1016/j.jad.2010.09.029 WOS:000290241600032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiat. 2003;60(10):1009–14. 10.1001/archpsyc.60.10.1009 WOS:000185815000008. [DOI] [PubMed] [Google Scholar]
  • 11.Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;(4):CD008965 10.1002/14651858.CD008965.pub4 [DOI] [PubMed] [Google Scholar]
  • 12.Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database of Systematic Reviews. 2014;(4). 10.1002/14651858.CD008965.pub4 CD008965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21(1):79–89. 10.1515/ijamh.2009.21.1.79 . [DOI] [PubMed] [Google Scholar]
  • 14.Harrington R, Adimadhyam S, Lee TA, Schumock GT, Antoon JW. The Relationship Between Oseltamivir and Suicide in Pediatric Patients. Ann Fam Med. 2018;16(2):145–8. 10.1370/afm.2183 WOS:000427596200008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Gjervig Hansen H, Kohler-Forsberg O, Petersen L, Nordentoft M, Postolache TT, Erlangsen A, et al. Infections, Anti-infective Agents, and Risk of Deliberate Self-harm and Suicide in a Young Cohort: A Nationwide Study. Biol Psychiatry. 2019;85(9):744–51. 10.1016/j.biopsych.2018.11.008 . [DOI] [PubMed] [Google Scholar]
  • 16.Ryu S, Kim S, Kim BI, Klein EY, Yoon YK, Chun BC. Temporal relationship between antibiotic use and respiratory virus activities in the Republic of Korea: a time-series analysis. Antimicrob Resist Infect Control. 2018;7:56–. 10.1186/s13756-018-0347-8 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Baldo V, Bertoncello C, Cocchio S, Fonzo M, Pillon P, Buja A, et al. The new pandemic influenza A/(H1N1)pdm09 virus: is it really "new"? Journal of preventive medicine and hygiene. 2016;57(1):E19–E22. . [PMC free article] [PubMed] [Google Scholar]
  • 18.Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain, behavior, and immunity. 2011;25(6):1272–8. Epub 05/14. 10.1016/j.bbi.2011.05.002 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Brundin L, Sellgren CM, Lim CK, Grit J, Pålsson E, Landén M, et al. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Translational psychiatry. 2016;6(8):e865 Epub 2016/08/03. 10.1038/tp.2016.133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Okusaga O, Duncan E, Langenberg P, Brundin L, Fuchs D, Groer MW, et al. Combined Toxoplasma gondii seropositivity and high blood kynurenine—Linked with nonfatal suicidal self-directed violence in patients with schizophrenia. Journal of psychiatric research. 2016;72:74–81. Epub 2015/11/26. 10.1016/j.jpsychires.2015.10.002 . [DOI] [PubMed] [Google Scholar]
  • 21.Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999;354(9173):131–2. 10.1016/S0140-6736(98)04793-X(98)04793-X. . [DOI] [PubMed] [Google Scholar]
  • 22.Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(1):85–102. 10.1016/s0278-5846(02)00338-x . [DOI] [PubMed] [Google Scholar]
  • 23.Yuan N, Chen Y, Xia Y, Dai J, Liu C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Translational psychiatry. 2019;9(1):233 10.1038/s41398-019-0570-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Oquendo MA, Sullivan GM, Sudol K, Baca-Garcia E, Stanley BH, Sublette ME, et al. Toward a biosignature for suicide. Am J Psychiatry. 2014;171(12):1259–77. 10.1176/appi.ajp.2014.14020194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory Virus Infections. Front Cell Neurosci. 2018;12:386–. 10.3389/fncel.2018.00386 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Fonken LK, Frank MG, Gaudet AD, Maier SF. Stress and aging act through common mechanisms to elicit neuroinflammatory priming. Brain, behavior, and immunity. 2018;73:133–48. Epub 07/17. 10.1016/j.bbi.2018.07.012 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hiltunen L, Suominen K, Lönnqvist J, Partonen T. Relationship between daylength and suicide in Finland. J Circadian Rhythms. 2011;9:10–. 10.1186/1740-3391-9-10 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Qin P, Mortensen PB, Waltoft BL, Postolache TT. Allergy is associated with suicide completion with a possible mediating role of mood disorder—a population-based study. Allergy. 2011;66(5):658–64. Epub 2010/12/15. 10.1111/j.1398-9995.2010.02523.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Woo JM, Gibbons RD, Rogers CA, Qin P, Kim JB, Roberts DW, et al. Pollen counts and suicide rates. Association not replicated. Acta Psychiatr Scand. 2012;125(2):168–75. Epub 12/19. 10.1111/j.1600-0447.2011.01813.x . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Yoon J-H, Jung SJ, Choi J, Kang M-Y. Suicide Trends over Time by Occupation in Korea and Their Relationship to Economic Downturns. Int J Environ Res Public Health. 2019;16(11):2007 10.3390/ijerph16112007 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Tan K, Prerna A, Leo Y-S. Surveillance of H1N1-related neurological complications. The Lancet Neurology. 2010;9(2):142–3. 10.1016/S1474-4422(10)70015-6 [DOI] [PubMed] [Google Scholar]
  • 32.Moller-Leimkuhler AM. The gender gap in suicide and premature death or: why are men so vulnerable? Eur Arch Psychiatry Clin Neurosci. 2003;253(1):1–8. Epub 2003/03/29. 10.1007/s00406-003-0397-6 . [DOI] [PubMed] [Google Scholar]
  • 33.van Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med. 2007;35(6):1464–9. Epub 2007/04/25. 10.1097/01.CCM.0000266534.14262.E8 . [DOI] [PubMed] [Google Scholar]
  • 34.Centers for Disease CaP. Flu Vaccine Safety Information: Do flu vaccines cause any side effects? 2017. Available from: https://www.cdc.gov/flu/prevent/general.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fprotect%2Fvaccine%2Fgeneral.htm. [Google Scholar]
  • 35.Vaccines IoMCtRAEo. Adverse Effects of Vaccines Evidence and Causality. Influenza Vaccine. Washington, D.C.: The National Academies Press; 2012. [Google Scholar]
  • 36.Sapuan S, Basri H. Acute Disseminated Encephalomyelitis (ADEM) Presenting with Bilateral Optic Neuritis. Malays J Med Sci. 2007;14(1):71–4. [PMC free article] [PubMed] [Google Scholar]
  • 37.Deshmukh IS, Bang AB, Jain MA, Vilhekar KY. Concurrent acute disseminated encephalomyelitis and Guillain-Barre syndrome in a child. J Pediatr Neurosci. 2015;10(1):61–3. 10.4103/1817-1745.154357 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Backer R, Tautman D, Lowry S, Harvey CM, Poklis A. Fatal ephedrine intoxication. J Forensic Sci. 1997;42(1):157–9. . [PubMed] [Google Scholar]

Decision Letter 0

Mrinmoy Sanyal

12 Jun 2020

PONE-D-20-10691

Fluctuations in influenza epidemics and suicide mortality: A time-series regression of 13-year mortality data

PLOS ONE

Dear Dr. Yoon,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 27 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Mrinmoy Sanyal, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Additional Editor Comments (if provided):

Please pay attention to the attachment provided by the Reviewer 1.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript investigates an association between suicide mortality and the rate of influenza-like illness (ILI) in Korea. The proposed study is exciting and timely as we experience a virus outbreak. Still, I am afraid that the presentation of statistical methods, data description, the measure of the unit of variables, and analysis is confusing.

I strongly recommend using consistent words for suicide mortality and ILI rate. Throughout the manuscript, I read suicide attempts, influenza symptoms, influenza infections were used instead of suicide mortality, and ILI rate that could distract any reader. Another confusing word was novel A(H1N1)pdm09. Do we have a difference between novel A(H1N1)pdm09, classic novel A(H1N1)pdm09, the new novel A(H1N1)pdm09, A(H1N1)pdm09? I think all are the same, but I would choose one name for the entire text.

I was able to access ILI data, but I couldn't find the suicide rate data.

Please see the attachment.

Reviewer #2: The authors investigated explored the association between influenza infection and suicide rates in a large population using a 57  time-series regression of 13-year mortality data This is an exceptionally timely and commendable work. Several short-comings are well acknowledged in the limitations section. The authors are urged to address the following points

1. Discuss implications and not only list differences between studies that find longer lags and, as as this study, that found shorter lags (here longer than 9 weeks results are not significant). The implications begin with biology- as longer lags imply a sequence of events of cummulation of risk before the maximum predictive association becomes manifest. The authors should discuss the potential of priming of immune cells , including resident immune cells in the brain- process that takes time, and makes the individual more vulnerable to innocuous immune, mechanical and psychological triggers. They could also discuss at a macro level differences between the first Danish study and their studies

2. Avoid the term suicidality. Although there is some terminological confusion, and examples of the use of the term the way the authors have used it so far, for majority of suicide researchers suicidality refers to suicidal ideation not behavior (behavior includes suicide = death by suicide, and non-fatal suicide attempts). The authors would do well to refer to previous studies on attempts as "suicidal behavior" and not suicidality (e.g. citation by Arling), and on studies on death by suicide- as suicide

3. In arguing that the results are not the effect of antivirals the authors write that a Longitudinal study did not find associations with antivirals, but did find associations with antibiotics. It is immortal to report, if data are available - what that percentage of viral infections lead to bacterial complications treated with antibiotics , and what of the percentage of confirmed influenza individuals end up on antibiotics in Korea. If antibiotics may increase risk of suicide - e.g. via reducing the immunomodulatory funciton of the gut microbiota, then it is possible, if large numbers of individuals end up being treated for (real or presumed) respiratory bacterial complications of Influenza, that the antibacterial treatment contributes to results.

4 There is a bit of lack of precision on citations being used, so that when referring the kynurenines- the authors cite nonspecific articles rather that very specific ones ,

a): Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, Mann

JJ, Postolache TT. Plasma kynurenine levels are elevated in suicide attempters

with major depressive disorder. Brain Behav Immun. 2011 Aug;25(6):1272-8. doi:

10.1016/j.bbi.2011.05.002. Epub 2011 May 14. PMID: 21605657; PMCID: PMC3468945.

b: Brundin L, Sellgren CM, Lim CK, Grit J, Pålsson E, Landén M, Samuelsson M,

Lundgren K, Brundin P, Fuchs D, Postolache TT, Traskman-Bendz L, Guillemin GJ,

Erhardt S. An enzyme in the kynurenine pathway that governs vulnerability to

suicidal behavior by regulating excitotoxicity and neuroinflammation. Transl

Psychiatry. 2016 Aug 2;6(8):e865. doi: 10.1038/tp.2016.133. PMID: 27483383;

PMCID: PMC5022080.

c: Okusaga O, Duncan E, Langenberg P, Brundin L, Fuchs D, Groer MW, Giegling I,

Stearns-Yoder KA, Hartmann AM, Konte B, Friedl M, Brenner LA, Lowry CA, Rujescu

D, Postolache TT. Combined Toxoplasma gondii seropositivity and high blood

kynurenine--Linked with nonfatal suicidal self-directed violence in patients

with schizophrenia. J Psychiatr Res. 2016 Jan;72:74-81. doi:

10.1016/j.jpsychires.2015.10.002. Epub 2015 Oct 9. PMID: 26594873.

For the immune activation and suicidal behavior- the citations that the author chose are neither the first, nor the most meta-analysis. We suggest replacing them either with the historically first - in the blood, in the CSF, in the brain or with the most recent several meta-analyses.

5 The authors correctly acknowledge overlaps between influenza and other immune and non immune mediated conditions occurring in spring such as pollen exposure and light- but it would be important to cite articles for those, and discuss lags involved in this study relative to the articles on lags of light exposure. The authors may also make the connection between influenza, sinus infections and allergic rhinitis by mentioning the nose/ upper airway to brain pathways for viruses, immune signals and immune cells, further affecting brain structure and function.

6. The differences between before 2009 pandemic and post 2009 pandemic require additional considerations- were there socioeconomic implications or individual psychological stress related to the pandemic contributing to risk. Even if speculative, this component will be very important for COVID-19. In that regard, at this stage the authors would be advised to comment on how the influenza pandemic was different from current COVID 19, and what expectations this article on influenza generates for pandemic of respiratory neurotropic viruses in general

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Teodor T. Postolache, MD

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-20-10691.pdf

PLoS One. 2021 Feb 12;16(2):e0244596. doi: 10.1371/journal.pone.0244596.r002

Author response to Decision Letter 0


24 Jul 2020

We would like to thank the Editor and reviewers for their valuable feedback on our submission to the PLos One. We found your comments to be very helpful in improving the quality of our manuscript. We attached our 'response to reviewer' file

Attachment

Submitted filename: response to reviewer 20200701.docx

Decision Letter 1

Mrinmoy Sanyal

16 Sep 2020

PONE-D-20-10691R1

Fluctuations in influenza epidemics and suicide mortality: A time-series regression of 13-year mortality data in South Korea

PLOS ONE

Dear Dr. Yoon,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address The Reviewer #1  comments and return the manuscript as soon as possible. (please see attachment for concerns highlighted in red).

Please submit your revised manuscript by Oct 31 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Mrinmoy Sanyal, PhD

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for incorporating my comments to revise the manuscript. I found some revisions are missing and highlighted in red color. I am still worried that the figures are blurred. Please see the attachment.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-20-10691_R1_referee_comments.pdf

Decision Letter 2

Mrinmoy Sanyal

14 Dec 2020

Fluctuations in influenza-like illness epidemics and suicide mortality: A time-series regression of 13-year mortality data in South Korea

PONE-D-20-10691R2

Dear Dr. Yoon,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Mrinmoy Sanyal, PhD

Academic Editor

PLOS ONE

Acceptance letter

Mrinmoy Sanyal

2 Feb 2021

PONE-D-20-10691R2

Fluctuations in influenza-like illness epidemics and suicide mortality: A time-series regression of 13-year mortality data in South Korea

Dear Dr. Yoon:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Mrinmoy Sanyal

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Box. Korean government’s guidelines for reporting “influenza-like illness”.

    (DOCX)

    Attachment

    Submitted filename: PONE-D-20-10691.pdf

    Attachment

    Submitted filename: response to reviewer 20200701.docx

    Attachment

    Submitted filename: PONE-D-20-10691_R1_referee_comments.pdf

    Attachment

    Submitted filename: response to reviewer 20201128.docx

    Data Availability Statement

    Data are available from the Korea statistical information system (KOSIS) Statistics DB Internet (http://kosis.kr/eng). The detail step is following: 1) mdis.kostat.go.kr, 2) Sign Up, 3) go to death record data under public health sector, 4) choose period of data set, 5) and download. Influenza monitoring data from 2004 to 2018 was available from KCDC website without any requirement for permission (http://www.cdc.go.kr/npt/biz/npp/iss/influenzaStatisticsMain.do).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES